



Coherus BioSciences to Report First Quarter 2016 Financial Results on May 9

REDWOOD CITY, Calif., May 02, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilar company with late-stage clinical products, today announced that it has scheduled a conference call for Monday, May 9, 2016 at 1:30 p.m. PT / 4:30 p.m. ET to discuss its first quarter 2016 financial results and product updates. Participating on the call will be Denny Lanfear, President and Chief Executive Officer, and Jean-Frédéric Viret, Ph.D., Chief Financial Officer. Prepared remarks will be followed by a question and answer session.

Financial results will be released over the wire after market close on Monday, May 9, 2016 and posted at <http://investors.coherus.com>.

Conference Call Information

When: Monday, May 9, 2016 at 1:30 p.m. PT
Dial-in: (844) 452-6826 (toll free) or (765) 507-2587 (International)
Conference ID: 2374783
Webcast: <http://investors.coherus.com>
Please join the conference call at least 10 minutes early to register.

About Coherus BioSciences, Inc.

Coherus is a leading pure-play global biosimilar platform company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products, including CHS-5217 (bevacizumab biosimilar) and CHS-3351 (ranibizumab biosimilar). For additional information, please visit www.coherus.com.

INVESTOR AND MEDIA CONTACT:

Keith Vendola, M.D.
Investor Relations
Coherus BioSciences, Inc.
kvendola@coherus.com
+1 (650) 437-6239



Coherus BioSciences, Inc.